Evidence map›Paper›PMID 40536328›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

DNase I-Mediated Chemotactic Nanoparticles for NETs Targeting and Microenvironment Remodeling Treatment of Acute Ischemic Stroke.

Tongyu Zhang, Peixin Liu, Wenru Shen, Chao Li, Zhenhao Zhao, Yuxing Wu, Tao Sun, Chen Jiang

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Immunomodulatory Nanozymes as Programmable Redox-Immune Set-Point Regulators.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tongyu ZhangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Fudan University, Shanghai, 201203, China.
Peixin LiuDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Fudan University, Shanghai, 201203, China.
Wenru ShenDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Fudan University, Shanghai, 201203, China.
Chao LiDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Fudan University, Shanghai, 201203, China.
Zhenhao ZhaoDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Fudan University, Shanghai, 201203, China.
Yuxing WuDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Fudan University, Shanghai, 201203, China.
Tao SunDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Fudan University, Shanghai, 201203, China.
Chen JiangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Fudan University, Shanghai, 201203, China.ORCID https://orcid.org/0000-0001-5223-2725

Funding

National Key R&D Program of China 2024YFA1210203National Natural Science Foundation of China 82273865Open Grant from the Pingyuan Laboratory 2023PY-OP-0106Shanghai Municipal Science and Technology Major Project 2018SHZDZX01ZJLab
6 · The paper itself

Abstract

The recruitment and formation of neutrophil extracellular traps (NETs) by neutrophils play an important role in reperfusion injury in ischemic stroke. Current nanosystem-based therapeutic strategies are mainly confined within the blood-brain barrier (BBB), ignoring the constant intrusion from external challenges. Here, considering the unique vascular localization of NETs, a DNase I-mediated NETs-targeting nanoparticle is developed to integrate the catalytic and chemotactic functions of DNase I and achieve the synergistic regulation of the internal and external microenvironment of the neurovascular unit (NVU). DNase I navigates the nanoparticles to the lesion, enabling the accumulation in the brain through damaged BBB. The removal of intravascular NETs mitigates the ongoing destruction of the endothelium and reduces the recruitment of immunothrombosis. The main nanoparticles with dual antioxidant activity rescue neuronal apoptosis by scavenging reactive oxygen species (ROS) and protecting mitochondria. Reduced infarct size and remodeling of microenvironment homeostasis shown in the middle cerebral artery occlusion/reperfusion (MCAO) mouse model. This strategy provides new insights into the vascular side treatment of ischemic stroke. Targeting mediated by enzyme chemotaxis is first validated and showed the potential of a universal chemotactic targeted delivery strategy.

Indexed as

Deoxyribonuclease IIschemic StrokeNanoparticlesAnimalsBlood-Brain BarrierBrainChemotactic FactorsChemotaxisDisease Models, AnimalHomeostasisHumansMaleMiceMice, Inbred C57BLNeuroprotectionNeutrophilsChemotactic FactorsDeoxyribonuclease IReactive Oxygen Speciesacute ischemic strokenanomedicineneurovascular unitneutrophil extracellular trapstargeted delivery

Identifiers

PMID40536328
PMCPMC12442667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.